To include your compound in the COVID-19 Resource Center, submit it here.

Dimension's intentions

Dimension maximizing full capsids for more potent, safer gene therapy

With an industry veteran at the helm and its lead program partnered and paid for, Dimension Therapeutics Inc. aims to develop safer and more potent gene therapies by packaging as many gene copies into capsids as possible.

Dimension debuted in 2013 with a series A round and an option to NAV vector technology from RegenxBio Inc. Dimension has since exercised the option to license exclusive, worldwide rights to a portfolio of liver-targeted AAV vectors for up to eight programs. Dimension's

Read the full 808 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers